Abstract
Aim: To investigate the level of agreement between three non-invasive methods for hrHPV diagnosis in oral and oropharyngeal squamous cell carcinoma (OSCC, OPSCC) and in oral mucosal lesions. Materials and Methods: For hrHPV DNA FTA Elute card™ and Anyplex II HPV28™ were used and for hrHPV mRNA PreTect SEE™ in tumour patients (n=60), non-tumour lesions (n=51), immunosuppression or previous hrHPV-infection (n=32). Results: The level of agreement between the DNA-methods was 82.2% (k=0.54, p=0.001). Pairwise comparison for the FTA Elute card were close to the reference (AUC=0.83, 95% CI=0.73-0.90). hrHPV mRNA was diagnosed in 50% of the tumours, with an agreement level of 58.3%, compared to Anyplex II (k=0.17, p=0.04). The hrHPV positivity in oral lesions was 3.9% for immunosuppression and for previous HPV infection 9.4%. Conclusion: The FTA card is reliable for hrHPV DNA diagnosis while mRNA gives an insight into viral activity and correlates with severity of the lesion.
Author supplied keywords
Cite
CITATION STYLE
STARK, C. R., GUSTAVSSON, I., HORAL, P., KOTOPOULI, M., GYLLENSTEN, U., & HIRSCH, J. M. (2021). Brush samples of oral lesions to FTA elute card for high-risk human papilloma virus diagnosis. Anticancer Research, 41(1), 269–277. https://doi.org/10.21873/anticanres.14773
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.